Woodford Patient Capital Trust PLC is a closed-ended investment company. The Company’s principal activity is investment in quoted and unquoted equities of companies incorporated or listed predominantly in the United Kingdom. The Company’s investment objective is to achieve long-term capital growth through investing in a portfolio consisting predominantly of the United Kingdom companies, both quoted and unquoted. The Company is focused on investing in mid and large-capitalization listed, mature companies; early-stage companies, which are typically quoted and unquoted companies. The Company’s portfolio is diversified across various sectors, which include healthcare, financials, industrials, technology, consumer goods and telecommunication industries.<\/p>\n\n\n\n
Its top ten holdings are:- <\/p>\n\n\n\n
Benevolentai 9.81% of the fund <\/p>\n\n\n\n
Oxford Nanopore Tech Ord 8.32% of the fund <\/p>\n\n\n\n
Autolus Therapeutics PLC ADR 8.26% of the fund <\/p>\n\n\n\n
Crossco (1337) Plc 8.07% of the fund <\/p>\n\n\n\n
Proton Partners Int Ltd ORD GBP0.001 7.34% of the fund <\/p>\n\n\n\n
IH HLDGS INTL LTD 6.74% of the fund <\/p>\n\n\n\n
Immunocore Ltd Series 5.64% of the fund <\/p>\n\n\n\n
Oxford Sciences Plc 4.62% of the fund <\/p>\n\n\n\n
IH HLDGS INTL LTD 2.97% of the fund <\/p>\n\n\n\n